Cargando…

Encephalitis following COVID-19 Vaccination: A Systematic Review

Background: Since the advent of global COVID-19 vaccination, several studies reported cases of encephalitis with its various subtypes following COVID-19 vaccinations. In this regard, we conducted a systematic review to investigate and characterize the clinical settings of these reported cases to aid...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhady, Mariam, Husain, Muhammad Ashraf, Hawas, Yousef, Elazb, Mahmoud Abdelsalam, Mansour, Lena Said, Mohamed, Mohamed, Abdelwahab, Maya Magdy, Aljabali, Ahmed, Negida, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054808/
https://www.ncbi.nlm.nih.gov/pubmed/36992160
http://dx.doi.org/10.3390/vaccines11030576
_version_ 1785015760778690560
author Abdelhady, Mariam
Husain, Muhammad Ashraf
Hawas, Yousef
Elazb, Mahmoud Abdelsalam
Mansour, Lena Said
Mohamed, Mohamed
Abdelwahab, Maya Magdy
Aljabali, Ahmed
Negida, Ahmed
author_facet Abdelhady, Mariam
Husain, Muhammad Ashraf
Hawas, Yousef
Elazb, Mahmoud Abdelsalam
Mansour, Lena Said
Mohamed, Mohamed
Abdelwahab, Maya Magdy
Aljabali, Ahmed
Negida, Ahmed
author_sort Abdelhady, Mariam
collection PubMed
description Background: Since the advent of global COVID-19 vaccination, several studies reported cases of encephalitis with its various subtypes following COVID-19 vaccinations. In this regard, we conducted a systematic review to investigate and characterize the clinical settings of these reported cases to aid in physician awareness and proper care provision. Methods: We systematically searched PubMed, Web of Science, and Scopus and manually searched Google Scholar. Studies published until October 2022 were included. Demographic data, clinical features, vaccine data, treatment lines, and outcomes were extracted. Results: A total of 65 patients from 52 studies were included. The mean age of patients was 46.82 ± 19.25 years, 36 cases (55.4%) were males. AstraZeneca was the most-reported vaccine associated with encephalitis (38.5%) followed by Pfizer (33.8%), Moderna (16.9%), and others. Moat encephalitis cases occurred after the first dose of vaccination in 41/65 (66.1%). The mean time between vaccination and symptom onset was 9.97 ± 7.16 days. Corticosteroids (86.2 %) and immunosuppressants (81.5 %) were the most used lines of treatment. The majority of affected individuals experienced a full recovery. Conclusion: Our study summarizes the current evidence of reported post-vaccination encephalitis, regarding clinical presentation, symptoms onset, management, outcomes, and comorbid conditions; however, it fails to either acknowledge the incidence of occurrence or establish a causal relationship between various COVID-19 vaccines and encephalitis.
format Online
Article
Text
id pubmed-10054808
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100548082023-03-30 Encephalitis following COVID-19 Vaccination: A Systematic Review Abdelhady, Mariam Husain, Muhammad Ashraf Hawas, Yousef Elazb, Mahmoud Abdelsalam Mansour, Lena Said Mohamed, Mohamed Abdelwahab, Maya Magdy Aljabali, Ahmed Negida, Ahmed Vaccines (Basel) Systematic Review Background: Since the advent of global COVID-19 vaccination, several studies reported cases of encephalitis with its various subtypes following COVID-19 vaccinations. In this regard, we conducted a systematic review to investigate and characterize the clinical settings of these reported cases to aid in physician awareness and proper care provision. Methods: We systematically searched PubMed, Web of Science, and Scopus and manually searched Google Scholar. Studies published until October 2022 were included. Demographic data, clinical features, vaccine data, treatment lines, and outcomes were extracted. Results: A total of 65 patients from 52 studies were included. The mean age of patients was 46.82 ± 19.25 years, 36 cases (55.4%) were males. AstraZeneca was the most-reported vaccine associated with encephalitis (38.5%) followed by Pfizer (33.8%), Moderna (16.9%), and others. Moat encephalitis cases occurred after the first dose of vaccination in 41/65 (66.1%). The mean time between vaccination and symptom onset was 9.97 ± 7.16 days. Corticosteroids (86.2 %) and immunosuppressants (81.5 %) were the most used lines of treatment. The majority of affected individuals experienced a full recovery. Conclusion: Our study summarizes the current evidence of reported post-vaccination encephalitis, regarding clinical presentation, symptoms onset, management, outcomes, and comorbid conditions; however, it fails to either acknowledge the incidence of occurrence or establish a causal relationship between various COVID-19 vaccines and encephalitis. MDPI 2023-03-02 /pmc/articles/PMC10054808/ /pubmed/36992160 http://dx.doi.org/10.3390/vaccines11030576 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Abdelhady, Mariam
Husain, Muhammad Ashraf
Hawas, Yousef
Elazb, Mahmoud Abdelsalam
Mansour, Lena Said
Mohamed, Mohamed
Abdelwahab, Maya Magdy
Aljabali, Ahmed
Negida, Ahmed
Encephalitis following COVID-19 Vaccination: A Systematic Review
title Encephalitis following COVID-19 Vaccination: A Systematic Review
title_full Encephalitis following COVID-19 Vaccination: A Systematic Review
title_fullStr Encephalitis following COVID-19 Vaccination: A Systematic Review
title_full_unstemmed Encephalitis following COVID-19 Vaccination: A Systematic Review
title_short Encephalitis following COVID-19 Vaccination: A Systematic Review
title_sort encephalitis following covid-19 vaccination: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054808/
https://www.ncbi.nlm.nih.gov/pubmed/36992160
http://dx.doi.org/10.3390/vaccines11030576
work_keys_str_mv AT abdelhadymariam encephalitisfollowingcovid19vaccinationasystematicreview
AT husainmuhammadashraf encephalitisfollowingcovid19vaccinationasystematicreview
AT hawasyousef encephalitisfollowingcovid19vaccinationasystematicreview
AT elazbmahmoudabdelsalam encephalitisfollowingcovid19vaccinationasystematicreview
AT mansourlenasaid encephalitisfollowingcovid19vaccinationasystematicreview
AT mohamedmohamed encephalitisfollowingcovid19vaccinationasystematicreview
AT abdelwahabmayamagdy encephalitisfollowingcovid19vaccinationasystematicreview
AT aljabaliahmed encephalitisfollowingcovid19vaccinationasystematicreview
AT negidaahmed encephalitisfollowingcovid19vaccinationasystematicreview